Pharmacodynamics of T-cell function for monitoring immunosuppression

Cell Proliferation

Volumn 40, Issue 1, 2007, Pages 50-63

  Barten, M J ^a   Tarnok, A ^a   Garbade, J ^a   Bittner, H B ^a   Dhein, S ^a   Mohr, F W ^a   Gummert, J F ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; GAMMA INTERFERON; INTERLEUKIN 2; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS;

ADJUVANT THERAPY; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CARDIAC GRAFT REJECTION; CELL FUNCTION; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE RELEASE; FEMALE; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; T LYMPHOCYTE;

AGED; ANTIGENS, SURFACE; CYCLOSPORINE; CYTOKINES; FEMALE; FLOW CYTOMETRY; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; PROLIFERATING CELL NUCLEAR ANTIGEN; SIROLIMUS; T-LYMPHOCYTES; TACROLIMUS; TIME FACTORS;

EID: 33846227941     PISSN: 09607722     EISSN: 13652184     Source Type: Journal    
DOI: 10.1111/j.1365-2184.2007.00413.x     Document Type: Article

References (22)

1. Barten MJ, van Gelder T, Gummert JF, Boecke K, Shorthouse R, Billingham M, Morris RE (2002) Pharmacodynamics of mycophenolate mofetil after heart transplantation: new mechanisms of action and correlations with histologic severity of graft rejection. Am. J. Transplant. 2, 719-732.
2. Barten MJ, Dhein S, Chang H, Bittner HB, Tarnok A, Rahmel A, Mohr FW, Gummert JF (2003) Assessment of immunosuppressive drug interaction: inhibition of lymphocyte function in peripheral human blood. J. Immunol. Methods 283, 99-114.
3. Barten MJ, Shipkova M, Bartsch P, Dhein S, Streit F, Tarnok A, Armstrong VW, Mohr FW, Oellerich M, Gummert JF (2005) Mycophenolic acid interaction with cyclosporine and tacrolimus in vitro and in vivo. Evaluation of additive effects on rat blood lymphocyte function. Ther. Drug Monit. 27, 123-131.
4. Barten MJ, Streit F, Boeger M, Dhein S, Tarnok A, Shipkova M, Armstrong VW, Mohr FW, Oellerich M, Gummert JF (2004) Synergistic effects of sirolimus and tacrolimus: analysis of immunosuppression on lymphocyte proliferation and activation in whole blood. Transplantation 77, 1154-1162.
5. van den Berg AP, Twilhaar WN, Mesander G (1998) Quantitation of immunosuppression by flow cytometric measurement of the capacity of T cells for interleukin-2 production. Transplantation 65, 1066-1071.
6. Brunet M, Campistol JM, Millan O, Vidal E, Esforzado N, Rojo I, Jimenez. O, Oppenheimer F, Corbella J, Martorell J (2003) Pharmacokinetic and pharmacodynamic correlations of cyclosporine therapy in stable renal transplant patients: evaluation of long-term target C2. Int. Immunopharmacol. 3, 987-999.
7. Budde K, Glander P, Bauer S, Braun K, Waiser J, Fritsche L, Mai I, Roots I, Neumayer HH (2000) Pharmacodynamic monitoring of mycophenolate mofetil. Clin. Chem. Lab. Med. 38, 1213-1216.
8. Cantarovich M, Elstein E, De Varennes B, Barkun JS (1999) Clinical benefit of Neoral dose monitoring with cyclosporine 2-hr post-dose levels compared with trough levels in stable heart transplant patients. Transplantation 68, 1839-1842.
9. Chang DM, Ding YA, Kuo SY, Chang ML, Wei J (1996) Cytokines and cell surface markers in prediction of cardiac allograft rejection. Immunol. Invest. 25, 13-21.
10. Dambrin C, Klupp J, Morris RE (2000) Pharmacodynamics of immunosuppressive drugs. Curr. Opin. Immunol. 12, 557-562.
11. Fitzpatrick DR, Kelso A (1998) Independent regulation of cytokine genes in T cells. Transplantation 65, 1-5.
12. van Gelder T, Hesselink DA, van Hest RM, Mathot RAA, van Schaik R (2004) Pharmacogenetics in immunosuppressive therapy: the best thing since TDM? Ther. Drug Monit. 26, 343-346.
13. Grinyó JM, Cruzado JM, Millán O, Caldes A, Sabate I, Gil-Vernet S, Seron D, Brunet M, Campistol JM, Torras J, Martorell J (2004) Low-dose cyclosporine with mycophenolate mofetil induces similar calcineurin activity and cytokine inhibition as does standard-dose cyclosporine in stable renal allografts. Transplantation 78, 1400-1403.
14. Gummert JF, Barten MJ, Sherwood SW, van Gelder T, Morris RE (1999) Pharmacodynamics of immunosuppression by mycophenolic acid: inhibition of both lymphocyte proliferation and activation correlates with pharmacokinetics. J. Pharmacol. Exp. Ther. 291, 1100-1112.
15. Härtel C, Fricke L, Schuhmacher N, Kirchner H, Müller- Steinhardt M (2002) Delayed cytokine mRNA expression kinetics after T-lymphocyte costimulation: a quantitative measure of the efficacy of cyclosporin A-based immunosuppression. Clin. Chem. 48, 2225-2231.
16. Hodge G, Hodge S, Reynolds P, Holmes M (2005) Intracellular cytokines in blood T cells in lung transplant patients - a more relevant indicator of immunosuppression than drug levels. Clin. Exp. Immunol. 139, 159-164.
17. Hutchinson P, Matthew J, Atkins RC, Holdsworth SR (2004) Ex vivo lymphocyte proliferative function is severely inhibited in renal transplant patients on mycophenolate mofetil treatment. Transpl. Immunol. 13, 55-61.
18. Kahan BD (2002) Therapeutic drug monitoring of immunosuppressant drugs in clinical practice. Clin. Ther. 24, 330-350.
19. Oellerich M, Barten MJ, Armstrong VW (2006) Biomarkers: the link between therapeutic drug monitoring and pharmacodynamics. Ther. Drug Monit. 28, 35-38.
20. Stalder M, Brisan T, Holm B, Haririfar M, Scandling J, Morris RE (2003) Quantification of immunosuppression by flow cytometry in stable renal transplant recipients. Ther. Drug Monit. 25, 22-27.
21. Stein CM, Murray JJ, Wood AJJ (1999) Inhibition of stimulated interleukin-2 production in whole blood: a practical measure of cyclosporine effect. Clin. Chem. 45, 1477-1484.
22. Weimer R., Melk A, Daniel V, Friemann S, Padberg W, Opelz. G (2000) Switch from cyclosporine A to tacrolimus in renal transplant recipients: impact on Th1, Th2, and monokine responses. Hum. Immunol. 61, 884-897.